Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial

被引:10
|
作者
Davis, Michael G. [1 ]
Piliang, Melissa P. [2 ,3 ]
Bergfeld, Wilma F. [2 ,3 ]
Caterino, Tamara L. [1 ]
Fisher, Brian K. [1 ]
Sacha, Jarek P. [1 ]
Carr, Gregory J. [1 ]
Moulton, Laura T. [1 ]
Whittenbarger, Deborah J. [1 ]
Schwartz, James R. [1 ]
机构
[1] Procter & Gamble Co, Mason, OH 45040 USA
[2] Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA
关键词
antioxidant; hair growth; hair loss; hair shedding; hair treatment; scalp; skin barrier; OXIDATIVE STRESS; ANDROGENETIC ALOPECIA; SEBORRHEIC DERMATITIS; PROTEIN OXIDATION; PYRITHIONE ZINC; DAMAGE; DISORDERS; MINOXIDIL; RADICALS; DANDRUFF;
D O I
10.1111/ics.12734
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Objective Increasing hair fullness is a global unmet need for many men and women. An approach to the problem is to decrease hair fall or shedding by reducing scalp stratum corneum oxidation and barrier damage to increase hair retention. This study evaluated a combination of functional antioxidants and barrier-enhancing cosmetic ingredients to improve scalp condition thereby enabling stronger hair anchorage and longer retention. Methods Male and female subjects with normal scalp condition and self-perceived hair thinning participated in a 24-week, double-blind, placebo-controlled, randomized clinical study assessing either a regimen of treatment shampoo and leave-on treatment containing functional antioxidant and barrier-enhancing agents or an identical placebo chassis shampoo control. The functional ingredients were piroctone olamine, zinc pyrithione, zinc carbonate, niacinamide, panthenol and caffeine. At baseline and after 8, 16 and 24 weeks of product use, several measurements were taken: hair shedding, total hair count (by phototrichogram), hair samples, TEWL and evaluation of biomarkers of scalp and hair conditions. Subjects also completed self-assessment questionnaires. Results Statistically significant effects for functional ingredient-containing treatment regimen versus a placebo control shampoo formulation were observed for reduced hair shedding, increased total hair count, reduced TEWL and improvement in scalp biomarker values. Subjects also noticed these improvements assessed via self-assessment questionnaires. Conclusions These results establish that the use of functional antioxidant and barrier-enhancing agents to further improve scalp condition can enable a reduction in hair shedding and thus an increase in perceived hair fullness. The underlying improvements in scalp condition suggest the hair benefits were achieved as a result of improved scalp skin barrier and scalp condition leading to a viable preventative approach for hair thinning.
引用
收藏
页码:S14 / S25
页数:12
相关论文
共 50 条
  • [1] Scalp application of the antioxidant piroctone olamine reduces hair shedding in an 8-week randomized, double-blind, placebo-controlled clinical study
    Davis, Michael G.
    Piliang, Melissa P.
    Bergfeld, Wilma F.
    Caterino, Tamara L.
    Fisher, Brian K.
    Sacha, Jarek P.
    Carr, Greg J.
    Moulton, Laura T.
    Whittenbarger, Deborah J.
    Punyani, Supriya
    Schwartz, James R.
    [J]. INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, 2021, 43 : S26 - S33
  • [2] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
    Rogers, SL
    Farlow, MR
    Doody, RS
    Mohs, R
    Friedhoff, LT
    Albala, B
    Baumel, B
    Booker, G
    Dexter, J
    Farmer, M
    Feighner, JP
    Ferris, S
    Gordon, B
    Gorman, DG
    Hanna, G
    Harrell, LE
    Hubbard, R
    Kennedy, J
    McCarthy, J
    Scharre, DW
    Schaerf, F
    Schneider, L
    Seltzer, B
    Siegal, A
    Stark, SR
    Strauss, A
    Walshe, TM
    [J]. NEUROLOGY, 1998, 50 (01) : 136 - 145
  • [3] The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
    Bagel, Jerry
    Duffin, Kristina Callis
    Moore, Angela
    Ferris, Laura K.
    Siu, Kimberly
    Steadman, Jennifer
    Kianifard, Farid
    Nyirady, Judit
    Lebwohl, Mark
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) : 667 - 674
  • [4] Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial
    Huerta-Ramos, Elena
    Labad, Javier
    Cobo, Jesus
    Nunez, Christian
    Creus, Marta
    Garcia-Pares, Gemma
    Cuadras, Daniel
    Franco, Jose
    Miquel, Eva
    Reyes, Julio-Cesar
    Marco-Garcia, Silvia
    Rodriguez, Carolina
    Rodriguez, Carolina
    Beneitez, Isabel
    Costa, Joan
    Castro, Lourdes
    Teba, Silvia
    Milian, Laura
    Foix, Alexandrina
    Rivero, Sonia
    Cavero, Marian
    Argemi, Maria
    Teba, Fernando
    Arranz, Belen
    Rubio, Elena
    Coromina, Marta
    Santos, Angeles
    Bogas, Jose Luis
    Barber, Ana
    Romans, Carlota
    Marquez, Manel
    Sabata, Anna
    Nieto, Lourdes
    Willikens, Eva
    Blanch, Enrich
    Acebillo, Siddharta
    Coronas, Ramon
    Ortega, Laura
    Coll, Ignasi
    Valero, Joaquin
    Rodriguez, Jesus
    Perez, Modesto
    Niubo, Ines
    Tost, Montse
    Monfort, Mari Pau
    Martorell, Lourdes
    Vilella, Elisabet
    Usall, Judith
    Huerta-Ramos, Elena
    Labad, Javier
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2020, 270 (06) : 729 - 737
  • [5] Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial
    Elena Huerta-Ramos
    Javier Labad
    Jesus Cobo
    Christian Núñez
    Marta Creus
    Gemma García-Parés
    Daniel Cuadras
    José Franco
    Eva Miquel
    Julio-César Reyes
    Silvia Marcó-García
    Judith Usall
    [J]. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270 : 729 - 737
  • [6] Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial
    Usall, Judith
    Huerta-Ramos, Elena
    Labad, Javier
    Cobo, Jesus
    Nunez, Christian
    Creus, Marta
    Garcia Pares, Gemma
    Cuadras, Daniel
    Franco, Jose
    Miquel, Eva
    Cesar Reyes, Julio
    Roca, Mercedes
    [J]. SCHIZOPHRENIA BULLETIN, 2016, 42 (02) : 309 - 317
  • [7] Donepezil improves cognition in patients with vascular dementia: Results from study 307, a 24-week, randomized, double-blind, placebo-controlled trial
    Roman, GC
    Pratt, RD
    Perdomo, CA
    Perdomo, CA
    [J]. NEUROBIOLOGY OF AGING, 2002, 23 (01) : S55 - S55
  • [8] Effects of Varenicline in Adult Smokers: A Multinational, 24-Week, Randomized, Double-Blind, Placebo-Controlled Study
    Bolliger, Chris T.
    Issa, Jaqueline S.
    Posadas-Valay, Rodolfo
    Safwat, Tarek
    Abreu, Paula
    Correia, Eurico A.
    Park, Peter W.
    Chopra, Pravin
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (04) : 465 - 477
  • [9] Atherosclerotic cardiovascular risk assessment in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin
    Gunn, Nadege T.
    Ling, Lei
    Neff, Guy
    Guy, Cynthia
    Bashir, Mustafa
    Paredes, Angelo
    Frias, Juan
    Younes, Ziad H.
    Trotter, James F.
    Moussa, Sam
    Kohli, Anita
    Connelly, Margery A.
    Nelson, Kristen
    Gottwald, Mildred
    Chang, William
    Yan, Andrew
    DePaoli, Alex
    Lieu, Hsiao
    Harrison, Stephen
    [J]. JOURNAL OF HEPATOLOGY, 2021, 75 : S617 - S617
  • [10] Effect of inorganic nitrate on metabolic parameters in patients with type 2 diabetes: A 24-week randomized double-blind placebo-controlled clinical trial
    Bahadoran, Zahra
    Norouzirad, Reza
    Mirmiran, Parvin
    Gaeini, Zahra
    Jeddi, Sajad
    Shokri, Majid
    Azizi, Fereidoun
    Ghasemi, Asghar
    [J]. NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2021, 107 : 58 - 65